LeblebiciogluH,CakirN,CelenM,KurtH,BarisH,LaeufferJ, 2012.Comparative activity of carbapenem testing (the COMPACT study) in Turkey,BMC Inf Dis 12 42 -
MartinezMJ,GarciaMI,SanchezGE,SanchezJE, 2010.Available carbapenems: properties and differences,Enferm Infecc Microbiol Clin 28 53 -64
SahmD., 2009.In vitro activity of doripenem,Clin Inf Dis 49 S11 -6
PatersonDL,DepestelDD, 2009.,Clin Inf Dis 49 291 -8
FirsovAA,GilbertD,GreerK,PortnoyYA,ZinnerSH, 2012.Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model,Antimicrob Agents Chemother 56 1223 -8
Wayne, 2014.8. Clinical and laboratory standards institute (CLSI). Performance standards for antimicrobial testing twenty fourth informational supplement,CLSI Document M100-S24 34 -
HojabriZ,Ahangarzadeh RezaeeM,NahaeiMR,SoroushMH,GhojazadehM,PirzadehT, 2013.Comparison of in vitro activity of doripenem versus old carbapenems against Pseudomonas aeruginosa clinical isolates from both CF and burn patients,Adv Pharma Bull 3 121 -5
KiratisinP,ChongthaleongA,TanTY,LagamayoE,RobertsS,GarciaJ, 2012.Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of AsiaPacific surveillance from the COMPACT II study,Int J Antimicrob Agents 39 311 -6
SomilyAM,AbsarMM,ArshadMZ,Al AskaAI,ShakoorZA,FataniAJ, 2012.Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline,Saudi Med J 33 750 -5
DongSX,WangJT,ChangSC, 2012.Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan,J Microbiol Immunol Infect 45 459 -64
MorrowBJ,PillarCM,DeaneJ,SahmDF,LynchAS,FlammRK, 2013.Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program,Diagn Microbiol Inf Dis 75 412 -6
LeeH,KoKS,SongJH,PeckKR, 2011.Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea,Microb Drug Resist 17 37 -45
ValenzaG,SeifertH,Decker-BurgardS,LaeufferJ,MorrisseyI,MuttersR, 2012.Comparative activity of carbapenem testing (COMPACT) study in Germany,Int J Antimicrob Agents 39 255 -8
KortenV,SoyletirG,YalcinAN,OguncD,DokuzoguzB,EsenerH, 2011.Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study,Mikrobiyol Bul 45 197 -209
LascolsC,LegrandP,MerensA,LeclercqR,Armand-LefevreL,DrugeonHB, 2011.In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints,Eur J Clin Microbiol Infect Dis 30 475 -82
JeanSS,HsuehPR,LeeWS,ChangHT,ChouMY,ChenIS, 2010.In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme,Eur J Clin Microbiol Infect Dis 29 471 -5
MartiS,Sánchez-CéspedesJ,AlbaV,VilaJ., 2009.In vitro activity of doripenem against Acinetobacter baumannii clinical isolates,Int J Antimicrob Agents 33 181 -2